In summary, there is an increasing range of options to process and obtain high titers and high-quality batches of viral vectors. We expect continued advancement and the future is open to new innovations and capabilities that should reduce complexity, lessen the challenges, and lower costs. In many ways, the industry is taking a similar path to the monoclonal antibody industry several years ago with expansive growth and manufacturing capabilities.
In closing, the Fibro units offer new flexibility and cost efficiency throughout multiple stages of product development. They compliment resin-based chromatography by providing benefits that resin-based chromatography doesn’t offer. In research and process development, Fibro’s faster purification can reduce development timelines. In clinical development, cost can be reduced by utilizing Fibro’s full Protein A lifetime in one batch. In manufacturing, Fibro’s cost-efficient single-use chromatography delivers more batches per year and allows large capital chromatography investments to be delayed until financial risks are reduced.